Clinical Trial Update: Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation [Phase 2]

View source ↗

Summary

Phase 2 trial comparing Abelacimab (MAA868) with rivaroxaban in atrial fibrillation assesses safety and tolerability; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation
• Stroke

Drugs mentioned

• Rivaroxaban (rivaroxaban)
• abeLacimab (abeLacimab)

Snippet

Sponsor: Anthos Therapeutics, Inc. | Conditions: Atrial Fibrillation (AF), Stroke | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-07-30